These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29551496)

  • 1. CR1 gene polymorphisms in Chinese patients with paroxysmal nocturnal hemoglobinuria.
    Long Z; Du Y; Li H; Han B
    Gene; 2018 Jun; 659():149-154. PubMed ID: 29551496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.
    Rondelli T; Risitano AM; Peffault de Latour R; Sica M; Peruzzi B; Ricci P; Barcellini W; Iori AP; Boschetti C; Valle V; Frémeaux-Bacchi V; De Angioletti M; Socie G; Luzzatto L; Notaro R
    Haematologica; 2014 Feb; 99(2):262-6. PubMed ID: 24038027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms in complement receptor 1 gene and its association with HBV-related liver disease: A case-control study.
    Luo J; Chen S; Wang J; Ou S; Zhang W; Liu Y; Qin Z; Xu J; Lu Q; Mo C; Li S; Qin X
    Gene; 2019 Mar; 688():107-118. PubMed ID: 30529247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persisting hyperbilirubinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with eculizumab: The role of hepatocanalicular transporter variants.
    Alashkar F; Weber SN; Vance C; Herich-Terhürne D; Dührsen U; Lammert F; Röth A
    Eur J Haematol; 2017 Oct; 99(4):350-356. PubMed ID: 28692147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association analysis of cytokine polymorphisms and plasma level in Northern Chinese Han patients with paroxysmal nocturnal hemoglobinuria.
    Wang SY; Yang XJ; Yang SS; Wang W; Tian YY; Cao FL; Zhou J
    Chin Med J (Engl); 2012 May; 125(9):1576-80. PubMed ID: 22800824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.
    Martí-Carvajal AJ; Anand V; Cardona AF; Solà I
    Cochrane Database Syst Rev; 2014 Oct; (10):CD010340. PubMed ID: 25356860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normal function of CR1 on affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria.
    Roberts WN; Wilson JG; Wong W; Jenkins DE; Fearon DT; Austen KF; Nicholson-Weller A
    J Immunol; 1985 Jan; 134(1):512-7. PubMed ID: 2578050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
    Cooper JP; Farah RJ; Stevenson PA; Gooley TA; Storb R; Scott BL
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1331-1339. PubMed ID: 30711779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
    Keating GM; Lyseng-Williamson KA; McKeage K
    BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Paroxysmal nocturnal hemoglobinuria and thrombosis in the era of eculizumab].
    Nishimura JI
    Rinsho Ketsueki; 2018; 59(8):1042-1047. PubMed ID: 30185704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
    Kanakura Y; Ohyashiki K; Shichishima T; Okamoto S; Ando K; Ninomiya H; Kawaguchi T; Nakao S; Nakakuma H; Nishimura J; Kinoshita T; Bedrosian CL; Valentine ME; Khursigara G; Ozawa K; Omine M
    Int J Hematol; 2011 Jan; 93(1):36-46. PubMed ID: 21222185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
    Peipert JD; Kulasekararaj AG; Gaya A; Langemeijer SMC; Yount S; Gonzalez-Fernandez FA; Ojeda Gutierrez E; Martens C; Sparling A; Webster KA; Cella D; Tomazos I; Ogawa M; Piatek CI; Wells R; Sicre de Fontbrune F; Röth A; Mitchell L; Hill A; Kaiser K
    PLoS One; 2020; 15(9):e0237497. PubMed ID: 32886668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variants in C5 and poor response to eculizumab.
    Nishimura J; Yamamoto M; Hayashi S; Ohyashiki K; Ando K; Brodsky AL; Noji H; Kitamura K; Eto T; Takahashi T; Masuko M; Matsumoto T; Wano Y; Shichishima T; Shibayama H; Hase M; Li L; Johnson K; Lazarowski A; Tamburini P; Inazawa J; Kinoshita T; Kanakura Y
    N Engl J Med; 2014 Feb; 370(7):632-9. PubMed ID: 24521109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of 512 eculizumab-naive paroxysmal nocturnal hemoglobinuria patients in China: a single-center observational study.
    Du Y; Yang Y; Yang C; Chen M; Han B
    Hematology; 2022 Dec; 27(1):113-121. PubMed ID: 35068377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria.
    Sicre de Fontbrune F; Peffault de Latour R
    Semin Hematol; 2018 Jul; 55(3):124-129. PubMed ID: 30032748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry.
    Villegas A; Núñez R; Gaya A; Cuevas-Ruiz MV; Bosch JM; Carral A; Arrizabalaga B; Gómez-Roncero MI; Mora A; Bravo P; Lavilla E; Monteserín C; Hernández B; Martínez-Barranco P; Jarque I; Urquía MA; García-Donas G; Brunet S; González FA; Urbano Á
    Ann Hematol; 2017 Oct; 96(10):1727-1733. PubMed ID: 28748287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of current treatments for paroxysmal nocturnal hemoglobinuria.
    Lee SE; Lee JW
    Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943
    [No Abstract]   [Full Text] [Related]  

  • 20. Alterations in markers of coagulation and fibrinolysis in patients with Paroxysmal Nocturnal Hemoglobinuria before and during treatment with eculizumab.
    van Bijnen ST; Østerud B; Barteling W; Verbeek-Knobbe K; Willemsen M; van Heerde WL; Muus P
    Thromb Res; 2015 Aug; 136(2):274-81. PubMed ID: 26143713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.